Arcus Biosciences Secures $100M Series B to Accelerate Breakthrough Cancer Therapies

Arcus Biosciences, a dynamic and rapidly growing global biopharmaceutical company, is thrilled to announce the successful raise of $100,000,000 in our latest funding round. This pivotal milestone not only underscores the confidence investors have in our clinical-stage initiatives but also marks a significant step forward in our quest to develop differentiated molecules and innovative combination medicines that may offer new hope and improved outcomes for people battling cancer. With our headquarters strategically located in the San Francisco Bay Area, we are proud to foster an environment that is as progressive as it is rewarding, offering competitive compensation, comprehensive benefits, and attractive stock option grants that actively involve our talented employees in the growth story of our company. The newly raised capital will be instrumental in accelerating our ambitious research and development programs and expanding our efforts in the discovery, development, and commercialization of novel combination therapies. These therapies are designed to address critical areas of unmet need in oncology and potentially extend the lives of cancer patients worldwide. At Arcus Biosciences, our team thrives in an exceptionally dynamic, team-driven environment where innovation is encouraged and the traditional “rule book” is continuously being rewritten to adapt to modern medical challenges. As we harness the power of this significant investment, we remain committed to pushing the boundaries of cancer treatment research and forging impactful partnerships that will revolutionize healthcare. This funding milestone marks the beginning of an exciting new chapter in our mission to become a formidable force in the biopharmaceutical landscape, dedicated to transforming patient care and making a meaningful difference in the fight against cancer.